

Corporate / Capital Summary

\$0.057

Share price
(as at 15 March 2023)

\$49.8M

Market
capitalisation

\$8.1M

Cash at bank*

~1,700

No. of shareholders

873.9M

Share on issue

156.9M[^]

NTIOA (13.5c) +
Other Options

~\$2.6M

R&D Investment
in FY22

55%

Top 20 Holders

*as at 31 December 2022

[^]Options are comprised at various strike prices between \$0.0

Clinical Pipeline – 2023

Pre-Clinical

NTI164
Combination Therapies
Prednisone, Diclofenac, Other

**Other Licensed
Strains**

Phase I/II

NTI164
Cerebral Palsy

NTI164
PANDAS / PANS

NTI164
ASD
(54 week open label extension)

NTI164
Rett Syndrome
(Expected 1H CY23)

Phase II/III

NTI164
ASD

Pipeline (2020/1)

NTI164
Combination Therapies
Prednisone, Diclofenac, Other

NTI164
Neuronal Cell Assays

Other Licensed Strains

